Neuren Pharmaceuticals Limited (NURPF)
USD 7.63
(10.58%)
USD 7.63
(10.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.69 Million AUD | 102.24% |
| 2022 | 16.15 Million AUD | 41.27% |
| 2021 | 11.43 Million AUD | 20.0% |
| 2020 | 9.53 Million AUD | -17.65% |
| 2019 | 11.57 Million AUD | 40.25% |
| 2018 | 8.25 Million AUD | 31.52% |
| 2017 | 6.27 Million AUD | -58.84% |
| 2016 | 15.24 Million AUD | -12.08% |
| 2015 | 17.34 Million AUD | 37.06% |
| 2014 | 12.65 Million AUD | 2.37% |
| 2013 | 12.36 Million AUD | 30.41% |
| 2012 | 9.47 Million AUD | 14.86% |
| 2011 | 8.25 Million AUD | -12.65% |
| 2010 | 9.44 Million AUD | 86.84% |
| 2009 | 5.05 Million AUD | -58.53% |
| 2008 | 12.19 Million AUD | -14.24% |
| 2007 | 14.21 Million AUD | 15.11% |
| 2006 | 12.35 Million AUD | 5.39% |
| 2005 | 11.71 Million AUD | 39.2% |
| 2004 | 8.41 Million AUD | 1539.22% |
| 2003 | 513.6 Thousand AUD | -2.17% |
| 2002 | 524.99 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.13 Million AUD | -43.41% |
| 2024 Q2 | 10.13 Million AUD | 0.0% |
| 2023 Q1 | 1.44 Million AUD | -83.54% |
| 2023 Q4 | 17.9 Million AUD | 1161.22% |
| 2023 FY | 32.68 Million AUD | 102.24% |
| 2023 Q3 | 1.41 Million AUD | -90.39% |
| 2023 Q2 | 14.77 Million AUD | 919.45% |
| 2022 Q2 | 7.33 Million AUD | 486.88% |
| 2022 Q1 | 1.24 Million AUD | -61.29% |
| 2022 Q3 | 206.5 Thousand AUD | -97.18% |
| 2022 Q4 | 8.8 Million AUD | 4164.41% |
| 2022 FY | 16.15 Million AUD | 41.27% |
| 2021 Q3 | 244 Thousand AUD | -97.02% |
| 2021 FY | 11.43 Million AUD | 20.0% |
| 2021 Q4 | 3.22 Million AUD | 1222.95% |
| 2021 Q1 | 514 Thousand AUD | -87.79% |
| 2021 Q2 | 8.19 Million AUD | 1494.16% |
| 2020 Q2 | 5.31 Million AUD | 1641.64% |
| 2020 Q4 | 4.2 Million AUD | 399.76% |
| 2020 Q3 | 842 Thousand AUD | -84.15% |
| 2020 Q1 | 305 Thousand AUD | -91.67% |
| 2020 FY | 9.53 Million AUD | -17.65% |
| 2019 FY | 11.57 Million AUD | 40.25% |
| 2019 Q2 | 7.9 Million AUD | 1238.53% |
| 2019 Q3 | 330.5 Thousand AUD | -95.82% |
| 2019 Q1 | 590.49 Thousand AUD | -66.6% |
| 2019 Q4 | 3.66 Million AUD | 1008.32% |
| 2018 Q3 | 1.76 Million AUD | 136.05% |
| 2018 Q1 | 748.99 Thousand AUD | -83.78% |
| 2018 Q4 | 1.76 Million AUD | 0.0% |
| 2018 FY | 8.25 Million AUD | 31.52% |
| 2018 Q2 | 748.99 Thousand AUD | 0.0% |
| 2017 Q1 | 745 Thousand AUD | 867.53% |
| 2017 FY | 6.27 Million AUD | -58.84% |
| 2017 Q3 | 4.61 Million AUD | 519.87% |
| 2017 Q2 | 745 Thousand AUD | 0.0% |
| 2017 Q4 | 4.61 Million AUD | 0.0% |
| 2016 Q2 | 936.5 Thousand AUD | 0.0% |
| 2016 FY | 15.24 Million AUD | -12.08% |
| 2016 Q1 | 936.5 Thousand AUD | 90.73% |
| 2016 Q4 | 77 Thousand AUD | 0.0% |
| 2016 Q3 | 77 Thousand AUD | -91.78% |
| 2015 FY | 17.34 Million AUD | 37.06% |
| 2015 Q4 | 491 Thousand AUD | 0.0% |
| 2015 Q1 | 520 Thousand AUD | 356.14% |
| 2015 Q2 | 520 Thousand AUD | 0.0% |
| 2015 Q3 | 491 Thousand AUD | -5.58% |
| 2014 Q3 | 114 Thousand AUD | -88.71% |
| 2014 Q1 | 1.01 Million AUD | -57.95% |
| 2014 Q4 | 114 Thousand AUD | 0.0% |
| 2014 FY | 12.65 Million AUD | 2.37% |
| 2014 Q2 | 1.01 Million AUD | 0.0% |
| 2013 Q3 | 2.4 Million AUD | 141.29% |
| 2013 FY | 12.36 Million AUD | 30.41% |
| 2013 Q2 | 995.49 Thousand AUD | 0.0% |
| 2013 Q1 | 995.49 Thousand AUD | 0.0% |
| 2013 Q4 | 2.4 Million AUD | 0.0% |
| 2012 FY | 9.47 Million AUD | 14.86% |
| 2011 FY | 8.25 Million AUD | -12.65% |
| 2010 FY | 9.44 Million AUD | 86.84% |
| 2009 FY | 5.05 Million AUD | -58.53% |
| 2008 FY | 12.19 Million AUD | -14.24% |
| 2007 FY | 14.21 Million AUD | 15.11% |
| 2006 FY | 12.35 Million AUD | 5.39% |
| 2005 FY | 11.71 Million AUD | 39.2% |
| 2004 FY | 8.41 Million AUD | 1539.22% |
| 2003 FY | 513.6 Thousand AUD | -2.17% |
| 2002 FY | 524.99 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | -200.883% |
| Skye Bioscience, Inc. | 13.54 Million USD | -141.35% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 12.236% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1366.313% |
| Qrons Inc. | 643.67 Thousand USD | -4979.722% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -7769.712% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -548.487% |
| BioStem Technologies, Inc. | 22.97 Million USD | -42.317% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3440.514% |
| CSL Limited | 3.44 Billion USD | 99.052% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 43.076% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -10.639% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4824.247% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2348.423% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -8293.186% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -104.226% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 62.324% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -564.855% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -12392.836% |
| SQZ Biotechnologies Company | 85.61 Million USD | 61.811% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1021.206% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2077.044% |
| Mesoblast Limited | 5.9 Million USD | -453.999% |
| Marizyme, Inc. | 19.23 Million USD | -69.944% |
| Genus plc | 147.7 Million USD | 77.863% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -272.436% |
| Pharming Group N.V. | 225.49 Million USD | 85.5% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1495.984% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2337.264% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -292.097% |
| ContraFect Corporation | 56.88 Million USD | 42.525% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -641.652% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2111.121% |
| IMV Inc. | 37.7 Million USD | 13.292% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1071.786% |
| MultiCell Technologies, Inc. | 567.42 USD | -5762298.224% |
| ONE Bio Corp. | 6.44 Million USD | -407.411% |
| Accustem Sciences Inc. | 3.74 Million USD | -772.753% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 61.956% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -6046.492% |
| Q BioMed Inc. | 3.43 Million USD | -851.427% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -32.296% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1144.404% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3188.834% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 67.083% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1758.124% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -386.706% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1653.783% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 130888.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1681.761% |
| GB Sciences, Inc. | 1.42 Million USD | -2201.781% |
| Alpha Cognition Inc. | 9.7 Million USD | -236.888% |
| HST Global, Inc. | 140.9 Thousand USD | -23104.667% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2806.633% |
| Halberd Corporation | 74.84 Thousand USD | -43588.036% |
| Enzolytics Inc. | 2.17 Million USD | -1400.202% |
| Agentix Corp. | 1.37 Million USD | -2283.587% |
| Resverlogix Corp. | 12.71 Million USD | -157.214% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -795.635% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 97.868% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3031.897% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1259.58% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1970.276% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -860.27% |
| AVAX Technologies, Inc. | 7.31 Million USD | -347.275% |
| Zenith Capital Corp. | 8.94 Million USD | -265.616% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.038% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -187587.274% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1231.681% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -18964.306% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1602.166% |
| Kadimastem Ltd | 2.41 Million USD | -1256.659% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1558.034% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -17916.365% |
| LadRx Corporation | 3.81 Million USD | -757.786% |
| Cell Source, Inc. | 4.32 Million USD | -655.94% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3440.514% |
| NovAccess Global Inc. | 2.46 Million USD | -1225.503% |
| Affymax, Inc. | 39.38 Million USD | 16.983% |
| Itoco Inc. | 919.14 Thousand USD | -3457.335% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -671.444% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2821.984% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5796.175% |
| CytoDyn Inc. | 18.05 Million USD | -81.067% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -129809.81% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -14757.005% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2202.943% |
| SYBLEU INC | 160.87 Thousand USD | -20224.349% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1700.178% |
| International Stem Cell Corporation | 5.27 Million USD | -520.319% |
| Bioxytran, Inc. | 3.82 Million USD | -755.909% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -62012.002% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -160628.506% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 9.841% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1920.828% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -4343.523% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -951.013% |
| Neutra Corp. | 243.82 Thousand USD | -13310.248% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -87.3% |
| PureTech Health plc | 144.59 Million USD | 77.387% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -59.576% |
| IXICO plc | 4.7 Million USD | -594.646% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -271.684% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 72.231% |
| CSL Limited | 3.89 Billion USD | 99.16% |
| Cellectis S.A. | 97.32 Million USD | 66.403% |